Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria

4Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Pathogenic mycobacteria species may subvert the innate immune mechanisms and can modulate the activation of cells that cause disease in the skin. Cutaneous mycobacterial infection may present different clinical presentations and it is associated with stigma, deformity, and disability. The understanding of the immunopathogenic mechanisms related to mycobacterial infection in human skin is of pivotal importance to identify targets for new therapeutic strategies. The occurrence of reactional episodes and relapse in leprosy patients, the emergence of resistant mycobacteria strains, and the absence of effective drugs to treat mycobacterial cutaneous infection increased the interest in the development of therapies based on repurposed drugs against mycobacteria. The mechanism of action of many of these therapies evaluated is linked to the activation of autophagy. Autophagy is an evolutionary conserved lysosomal degradation pathway that has been associated with the control of the mycobacterial bacillary load. Here, we review the role of autophagy in the pathogenesis of cutaneous mycobacterial infection and discuss the perspectives of autophagy as a target for drug development and repurposing against cutaneous mycobacterial infection.

Cite

CITATION STYLE

APA

Bittencourt, T. L., da Silva Prata, R. B., de Andrade Silva, B. J., de Mattos Barbosa, M. G., Dalcolmo, M. P., & Pinheiro, R. O. (2021, May 25). Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2021.674241

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free